BioSpace News Archive

Nextleaf Solutions Ltd. Achieves Strong Fiscal Year 2023 Financial Performance, Debt-Free Status, and Positive Cash Flow from Operations

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, or the “Company”), a multi-patented biotech company, and Canadian-based cannabis processor with a commercialized portfolio of federally regulated adult-use brands

January 31, 2024
·
8 min read
Drug Development

InFlectis BioScience Completes Enrollment of Its Phase 2 Trial of IFB-088 for the Treatment of Amyotrophic Lateral Sclerosis; Anticipates Initial Results Later This Year

InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has completed enrollment in its Phase 2

January 31, 2024
·
1 min read
BioMidwest

Medline signs strategic partnership with St. Luke’s in Duluth, MN

Medline has announced the signing of a five-year primary supplier vendor agreement with St. Luke’s, headquartered in Duluth, Minnesota.

January 31, 2024
·
2 min read
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Galapagos NV announced the successful completion of the transaction to transfer its Jyseleca® business to Alfasigma S.p.A.

January 31, 2024
·
7 min read
Genetown

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Xilio Therapeutics, Inc. will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST.

January 31, 2024
·
1 min read
Genetown

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics, Inc. announced that it has received notice from the NASDAQ Stock Market LLC that the Nasdaq has determined that the Company has regained compliance with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550 for continued listing on the Nasdaq Capital Market.

January 31, 2024
·
4 min read
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S announced that YORVIPATH®, a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria.

January 31, 2024
·
6 min read
Biotech Beach

Personalis to Participate at Upcoming Investor Conferences - Jan 31, 2024

Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will participate at the following investor conferences.

January 31, 2024
·
1 min read
Biotech Bay

ORIC Pharmaceuticals to Participate in Upcoming February 2024 Investor Conferences

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in February.

January 31, 2024
·
1 min read
Business

DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations

DermTech, Inc. announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses.

January 31, 2024
·
5 min read